<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916925</url>
  </required_header>
  <id_info>
    <org_study_id>PCOS resistant to CC &amp; vit D</org_study_id>
    <nct_id>NCT04916925</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D Oral Supplementation in Poly Csytic Ovarian Women Resistant to Clomiphene Citrate</brief_title>
  <official_title>Effect of Vitamin D Oral Supplementation in Poly Cystic Ovarian Women Resistant to Clomiphene Citrate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>rana alaaeldin aly ibrahim nasr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      effect of vitamin D oral supplementation in poly csytic ovarian women resistant to clomiphene&#xD;
      citrate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovarian syndrome is the most common endocrine disorder . It is associated with&#xD;
      chronic anovulation and infertility. The diagnosis is made by clinical and ancillary&#xD;
      investigations revealing the presence of irregular menstrual cycles, an ovulation ,&#xD;
      Hyperandrgenemia , and the presence of polycystic ovaries (ovarian morphology as the presence&#xD;
      of 12 or more follicles measuring 2-9 mm in diameter and an increased ovarian volume &gt;10 cm&#xD;
      3) ovulation can be induced with clomiphene citrate (CC), However, ~20%-25% of anovulatory&#xD;
      women with PCOS do not respond to CC and are considered to be &quot;clomiphene-resistant(&#xD;
      clomiphene citrate resistance means failure to ovulate with 3 months use of clomid at 150&#xD;
      mg/day for 5 days ) Vitamin D may serve as a key in preventing and attenuating the insulin&#xD;
      resistance. Vitamin D plays a physiologic role in reproduction including ovarian follicular&#xD;
      development and luteinisation, follicle-stimulating hormone sensitivity and progesterone&#xD;
      production in human granulosa cells. It also affects glucose homeostasis .&#xD;
&#xD;
      In this trial 100 women with PCO disease that diagnosed by ROTTERDAM CRITERIA (must have any&#xD;
      TWO of This findings: Hyperandrogenism, Oligomenorrhea, Polycystic ovaries). Who are taking&#xD;
      clomiphene citrate for induction of ovulation and resistant to it, which means failure to&#xD;
      ovulate with 3 months of usage of clomid at 150 mg/day for 5 days. They will recieve vitamin&#xD;
      D (ossofortinÂ®, Eva Pharma) orally 10000 IU twice weekly for other three months period with&#xD;
      clomiphene citrate orally 150 mg/day for 5 days. Number and size of the growing follicles&#xD;
      will be monitored before and after taking vitamin D by trans-vaginal ultrasound at day11-14&#xD;
      of the cycle till day 21 to detect effect of vitamin D in ovulation rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 21, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>a single arm clinical trail</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of the ovulated follicles</measure>
    <time_frame>36 hours of taking HCG injection</time_frame>
    <description>Number of ovulated follicles by trans vaginal ultra sound signs of ovulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pregancy rate</measure>
    <time_frame>2 days after delayed menses</time_frame>
    <description>Pregnancy test positive by quantititave see beta HCG level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the endometrial thickness</measure>
    <time_frame>36 hour of taking HCG</time_frame>
    <description>Measure the endometrium thickness by transvaginal ultrasound</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <condition>Clomiphene Allergy</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>pcos resistant to cc plus vit d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 patients who are PCOS and resist CC will receive Vitamin D 10000 IU orally plus 150mg clomid orally for 3 months number and size of growing follicles will be monitored</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>Adding vitamin D to PCOS patients who are resistant to clomiphene regime for induction will or not improve the Clinical pregnancy rate and will or not increase chances of ovulation and pregnancy.</description>
    <arm_group_label>pcos resistant to cc plus vit d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomid</intervention_name>
    <description>CLOMID is adrug used for ovulation induction</description>
    <arm_group_label>pcos resistant to cc plus vit d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-40 years 2- Polycystic ovarian syndrome diagnosis made according to ESHRE/ASRM&#xD;
             criteria.&#xD;
&#xD;
               1. Polycystic ovaries (either 12 or more follicles or increased ovarian volume [&gt; 10&#xD;
                  cm3&#xD;
&#xD;
               2. Oligo-ovulation or anovulation&#xD;
&#xD;
               3. Clinical and/or biochemical signs of hyperandrogenism (Azziz, 2006). 3- PCOS&#xD;
                  infertile women resistant to CC for 3 cycles. clomiphene citrate resistance means&#xD;
                  failure to ovulate with 3 months use of clomid at 150 mg/day for 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Causes of infertility other than PCOS.&#xD;
&#xD;
               1. Male factor.(normal semen analysis)&#xD;
&#xD;
               2. Other factors e.g. endometriosis&#xD;
&#xD;
               3. Tubal factor. (normal hysterosalpingography)&#xD;
&#xD;
               4. Premature ovarian failure: Day 3 FSH &gt; 14 mlu/ml or antimullerian hormone &lt;1&#xD;
                  ng/ml.&#xD;
&#xD;
               5. Normal ultrasound except for criteria of PCO&#xD;
&#xD;
          -  Causes of anovulation other than PCOS.&#xD;
&#xD;
          -  Patients with hyperprolactinemia&#xD;
&#xD;
          -  Patients with thyroid dysfunction.&#xD;
&#xD;
          -  Current or in last six months use of vit D treatment.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>in child bearing age</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>rana nasr</last_name>
    <phone>01274901443</phone>
    <email>roona_015@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>alhassan khedr</last_name>
    <phone>01006193797</phone>
    <email>alhassankhedr@med.asu.edu.eg</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>rana alaaeldin aly ibrahim nasr</investigator_full_name>
    <investigator_title>Clinical gynecology professor</investigator_title>
  </responsible_party>
  <keyword>Poly cystic ovary syndrome</keyword>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

